keyword
MENU ▼
Read by QxMD icon Read
search

Phentermine/topiramate

keyword
https://www.readbyqxmd.com/read/28595525/obesity-induced-hypertension-new-insights
#1
Christina Antza, Stella Stabouli, Michalis Natsis, Ioannis Doundoulakis, Vasilios Kotsis
BACKGROUND: New insights on the relationship between weight loss and hypertension and the role of the newly approved anti-obesity drugs on hypertension will be discussed Methods: Weight loss is a major factor to reduce blood pressure when a patient with excess weight is advised from the health care provider to change his lifestyle. A healthy lifestyle with reduction in body weight, reduction in caloric intake, increased fruit and vegetables consumption and reduced salt intake concomitant with an increase in physical exercise can reduce body weight and hypertension in overweight and obese patients, but not all obese are able to reduce their blood pressure and lose weight without treatment and special dietary care...
June 7, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28462579/pharmacological-management-of-obesity
#2
Amanda Velazquez, Caroline M Apovian
Current management of obesity includes three main arms: behavioral modification, pharmacologic therapy, and bariatric surgery. Decades prior, the only pharmacological agents available to treat obesity were approved only for short-term use (≤ 12 weeks) by the Food and Drug Administration (FDA). However, in the last several years, the FDA has approved several medications for longer term treatment of obesity. This highlights the important progression that we, as a society, better appreciate now the chronicity and complexity of obesity as a disease...
April 28, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/28455281/cardiometabolic-disease-staging-predicts-effectiveness-of-weight-loss-therapy-to-prevent-type-2-diabetes-pooled-results-from-phase-iii-clinical-trials-assessing-phentermine-topiramate-extended-release
#3
Fangjian Guo, W Timothy Garvey
OBJECTIVE: To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score. RESEARCH DESIGN AND METHODS: We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL- assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER...
April 28, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28421338/tailoring-pharmacotherapy-to-specific-eating-behaviours-in-obesity-can-recommendations-for-personalised-therapy-be-made-from-the-current-data
#4
Carl A Roberts, Paul Christiansen, Jason C G Halford
Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorcaserin and phentermine/topiramate, which have FDA approval only. Each of the six drugs, used singly or in combination, has distinct pharmacological, and presumably distinct behavioural, mechanisms of action, thus the potential to provide defined therapeutic options to personalise the management of obesity...
April 19, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/28392927/liraglutide-for-weight-management-a-critical-review-of-the-evidence
#5
A Mehta, S P Marso, I J Neeland
OBJECTIVE: To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials. METHODS: A search of the English language literature was performed using PubMed search terms: "liraglutide", "glucagon-like peptide-1 receptor agonist", and "randomized clinical trial". Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included. RESULTS: Five randomized, placebo-controlled trials of liraglutide for weight management were identified...
March 2017: Obesity Science & Practice
https://www.readbyqxmd.com/read/28378293/pharmacotherapy-of-obesity-clinical-trials-to-clinical-practice
#6
REVIEW
Kishore M Gadde, Y Pritham Raj
PURPOSE OF REVIEW: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies-lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg-which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice...
May 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28245771/current-drug-targets-in-obesity-pharmacotherapy-a-review
#7
Sangeeta P Bhat, Arun Sharma
Obesity, an impending global pandemic, is not being effectively controlled by current measures such as lifestyle modifications, bariatric surgery or available medications. Its toll on health and economy compels us to look for more effective measures. Fortunately, the advances in biology and molecular technology have been in our favour for delineating new pathways in the pathophysiology of obesity and have led to subsequent development of new drug targets. Development of anti-obesity drugs has often been riddled with problems in the past...
February 27, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/27773782/obesity-current-and-potential-pharmacotherapeutics-and-targets
#8
REVIEW
Vidya Narayanaswami, Linda P Dwoskin
Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally-derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior...
February 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27732121/safety-assessment-of-combination-therapies-in-the-treatment-of-obesity-focus-on-naltrexone-bupropion-extended-release-and-phentermine-topiramate-extended-release
#9
REVIEW
Bruno Halpern, Marcio C Mancini
Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval. Areas covered: In this review, we discuss safety concerns about both combinations, the rationale and history of combination therapies for obesity (including phentermine plus fenfluramine), and possible future new combinations...
January 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27583422/update-on-office-based-strategies-for-the-management-of-obesity
#10
Michael Erlandson, Laurie C Ivey, Katie Seikel
Obesity is a common condition that is associated with numerous medical problems such as cardiovascular disease, pulmonary disease, and diabetes mellitus. Primary care physicians have an important role in helping patients develop a successful weight loss plan to improve their overall health. Dietary strategies emphasizing reduced caloric intake, regardless of the nutrient composition, are important for weight loss. Behavioral interventions such as motivational interviewing and encouraging physical activity lead to additional weight loss when combined with dietary changes...
September 1, 2016: American Family Physician
https://www.readbyqxmd.com/read/27565106/answers-to-clinical-questions-in-the-primary-care-management-of-people-with-obesity-pharmacologic-management
#11
Ken Fujioka, Jill Braverman-Panza
The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat). Indicated for the treatment of patients with overweight (body mass index [BMI] ≥27 kg/m2 with ≥1 weight-related comorbidity) or obesity (BMI ≥30 kg/m2), these medications provide new opportunities to address this burgeoning health problem.
July 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27539178/cardiovascular-effects-of-the-new-weight-loss-agents
#12
REVIEW
Matthew H Vorsanger, Pritha Subramanyam, Howard S Weintraub, Steven H Lamm, James A Underberg, Eugenia Gianos, Ira J Goldberg, Arthur Z Schwartzbard
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described...
August 23, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27299618/association-of-pharmacological-treatments-for-obesity-with-weight-loss-and-adverse-events-a-systematic-review-and-meta-analysis
#13
REVIEW
Rohan Khera, Mohammad Hassan Murad, Apoorva K Chandar, Parambir S Dulai, Zhen Wang, Larry J Prokop, Rohit Loomba, Michael Camilleri, Siddharth Singh
IMPORTANCE: Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited. OBJECTIVE: To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries. STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo...
June 14, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27277818/exploratory-literature-meta-analysis-to-characterize-the-relationship-between-early-and-longer-term-body-weight-loss-for-antiobesity-compounds
#14
Nele Plock, Leon Bax, Douglas Lee, Deborah DeManno, Gezim Lahu, Marc Pfister
The presented analysis was performed to characterize the relationship between treatment-related early (week 4) and longer term (3-6 months) weight loss to understand the potential utility of 4-week proof-of-mechanism studies in the early decision-making process during clinical development of new antiobesity compounds. A regression-based meta-analysis was performed leveraging publically available clinical outcomes data to (1) characterize the within-trial relationship between treatment-related early and longer term body weight loss and (2) identify and quantify key covariate effects on this relationship...
January 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27236593/precision-obesity-treatments-including-pharmacogenetic-and-nutrigenetic-approaches
#15
REVIEW
Maite Solas, Fermin I Milagro, Diego Martínez-Urbistondo, Maria J Ramirez, J Alfredo Martínez
Five pharmaceutical strategies are currently approved by the US FDA for the treatment of obesity: orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone. The most effective treatment seems to be the combined administration of phentermine/topiramate followed by lorcaserin and bupropion/naltrexone. In relation to the management of excessive weight, other aspects also need to be considered, including comorbidities accompanying obesity, drug interactions, and the risk of negative collateral effects, as well as individualized treatments based on the genetic make-up...
July 2016: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/27199749/stimulants-for-the-control-of-hedonic-appetite
#16
Alison S Poulton, Emily J Hibbert, Bernard L Champion, Ralph K H Nanan
The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behavior. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognized to be effective for treating obesity. However, stimulants can be abused for their euphoric effect...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27181165/pharmacologic-approaches-to-weight-management-recent-gains-and-shortfalls-in-combating-obesity
#17
REVIEW
Katherine H Saunders, Rekha B Kumar, Leon I Igel, Louis J Aronne
Obesity is a growing epidemic in the USA with over one third of adults presently classified as obese. Obesity-related comorbidities include many leading causes of preventable death such as heart disease, stroke, type 2 diabetes, and certain types of cancer. Modest weight loss of 5-10 % of body weight is sufficient to produce clinically relevant improvements in cardiovascular disease risk factors among patients with overweight and obesity. Until recently, there were limited pharmacologic options approved by the Food and Drug Administration to treat obesity...
July 2016: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/27114740/effectiveness-tolerability-and-practical-application-of-the-newer-generation-anti-obesity-medications
#18
REVIEW
Jeffrey S MacDaniels, Thomas L Schwartz
OBJECTIVE: Comparison of the efficacy and tolerability of five newer anti-obesity medications to guide clinical decision making, examining bupropion-naltrexone combination, liraglutide, lorcaserin, orlistat, and phentermine-topiramate combination. METHODS: A brief literature review and internet search for high-powered, randomized and placebo-controlled drug trials was conducted. Drug trial information was established for five currently approved anti-obesity medications...
2016: Drugs in Context
https://www.readbyqxmd.com/read/27086785/obesity-the-metabolic-disease-advances-on-drug-discovery-and-natural-product-research
#19
REVIEW
Mafalda Castro, Marco Preto, Vitor Vasconcelos, Ralph Urbatzka
Obesity is a global health threat. OECD reported that more than half (52%) of the adult population in the European Union is overweight or obese. Obesity and obesity-related co-morbidities have deep negative effects on morbidity, mortality, professional and personal quality of life. Healthcare costs represent a negative impact of this disease, with an associated economic cost of 100 billion US$ per year in the United States. The most prescribed drugs for obesity treatment worldwide are orlistat, and phentermine/topiramate extended release, while the major prescribed drug for the same disease in the US are exenatide and dapagliflozin...
2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/27063550/regulation-of-food-intake-and-the-development-of-anti-obesity-drugs
#20
REVIEW
Yue Chen
As the most significant cause of death worldwide, obesity has become one of the world's most important public health problems, but approved anti-obesity drugs are extremely limited. This article summarizes the feeding control circuits and regulators involved in obesity development, highlight the hypothalamus, melanocortin system and brain-gut peptide actions in this process, and the five US FDA approved anti-obesity medications in long term use, namely phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide and orlistat...
2016: Drug Discoveries & Therapeutics
keyword
keyword
78942
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"